Injective chief says INJ ETF timeline is moving faster than expected
Injective co-founder and CEO Eric Chen has said he expects United States exchange-traded funds tied to INJ to launch before 2027, a timeline he described as arriving “way sooner than I expected.”
Speaking to The Block at Korea Blockchain Week 2026, Chen was direct about the pace of progress. “2027 is a little bit too far,” he said, signalling that the approval and launch window for INJ-linked products is compressing faster than the project had anticipated. He did not offer a specific launch date, but the thrust of his remarks was clear: the regulatory machinery is turning, and turning quickly.
The comments centre on two pending filings with the Securities and Exchange Commission: the 21Shares Injective ETF and the Canary Staked INJ ETF. According to the SEC’s website, both were initially filed in 2025. Both issuers submitted amended S-1 registration statements in September 2026, a strong indication that the applications remain active and are advancing through the review process rather than sitting dormant in the queue.
Why amended S-1s matter
In the world of crypto ETF applications, paperwork movement is often the most reliable signal available to observers. An amended S-1 registration statement is not an approval, and it is not a guarantee of one. What it demonstrates is engagement. Issuers amend when they are responding to SEC comments, refining product structures, or preparing disclosures to a standard the regulator will accept. Dormant applications do not generate amendments.
The fact that both 21Shares and Canary filed updated registrations in the same month suggests a coordinated phase of refinement, with each issuer working through the regulator’s feedback in parallel. For a token tied to a Layer 1 blockchain, that is a meaningful milestone. The SEC’s historical caution toward proof-of-stake assets, particularly around questions of custody, securities classification, and staking mechanics, has made the path to market for tokens like INJ slower and more uncertain than the route Bitcoin took.
Chen’s confidence, then, is not idle optimism from a founder talking up his own token. It is anchored to observable regulatory activity. Two issuers, two amended filings, and a public comment from the executive closest to the project all point in the same direction.
The staking angle deserves particular attention. The Canary Staked INJ ETF, as its name suggests, would not simply track the spot price of INJ. It would wrap staking exposure into a regulated wrapper, meaning the fund itself could participate in the network’s staking process and pass yield through to shareholders. That product design matters because it tests whether the SEC will tolerate yield-bearing crypto structures inside an ETF chassis, a question that has hung over the industry since staking was stripped out of early spot Bitcoin ETF proposals.
Market implications: regulated access and demand expansion
The significance of an INJ ETF extends well beyond a single product launch. ETF approvals have become the primary route for mainstream access to crypto assets in the United States. The spot Bitcoin ETFs demonstrated the scale of that demand, and issuers have since raced to replicate the model across a widening set of tokens. Each new approval normalises the next one.
For Injective, a US-listed ETF would give investors a regulated vehicle to gain exposure to INJ without holding the token directly, without managing private keys, and without navigating offshore exchanges. That matters for two distinct audiences. Institutional allocators, including advisers and funds constrained by custody and compliance requirements, gain a compliant on-ramp. Retail investors gain the familiarity of a brokerage-listed product they can hold in an ordinary account.
The potential effect on demand is twofold. First, an ETF creates a structural buyer: the issuer must acquire and custody the underlying asset to back its shares. Second, it broadens the base of holders beyond the existing crypto-native population. Whether that translates into sustained price appreciation depends on flows, but the mechanism is well established from prior launches.
The staked variant adds a further layer. If the Canary Staked INJ ETF reaches market, it would offer exposure to INJ plus staking yield inside a single regulated instrument. That could appeal to income-focused investors who have so far stayed away from crypto because holding the asset produced no return and carried operational risk. It would also set a precedent for other proof-of-stake networks eyeing similar structures.
Injective’s regulatory positioning extends beyond the ETF track. The project has been expanding in the United States through SEC-registered transfer agent status, and in Europe through a MiCA white paper filing under the EU’s Markets in Crypto-Assets regime. Those developments are separate from ETF approval, but they form a coherent picture: a project deliberately building the compliance infrastructure that regulated finance requires. Transfer agent status in particular signals intent to operate within US securities rails, which is consistent with a strategy aimed at tokenised and regulated products rather than purely decentralised speculation.
Readers tracking the wider institutional push can follow developments across the sector in our ETF coverage, where we document filings, amendments, and approvals as they happen.
Regulatory context and what to watch next
The INJ filings sit within a broader shift in the SEC’s posture toward crypto. The 2025 filing dates for both products place them in the wave of applications that followed the industry’s post-Bitcoin-ETF confidence, when issuers moved from asking whether crypto ETFs were possible to asking which tokens would be next. The September 2026 amendments indicate that the review process, whatever its pace, has not stalled.
For Injective specifically, the Layer 1 context matters. INJ is not a payment token or a stablecoin; it is the native asset of a blockchain focused on finance, used for staking, governance, and network fees. That profile cuts both ways in regulatory terms. It gives the asset a clear functional purpose within its network, which supports arguments against treating it as a pure speculative instrument. At the same time, staking and governance features have historically drawn closer scrutiny from the SEC, which is why the staked ETF variant is the more ambitious of the two filings.
The near-term watch items are straightforward. Further amendments to either S-1 would signal continued engagement. A filing effectiveness date would move the process into its final stage. Chen’s own framing, that 2027 is “a little bit too far,” suggests the project expects movement within roughly a year, though he stopped short of naming a date, and investors should treat the absence of a specific timeline as a reason for caution rather than a green light.
The bottom line
Eric Chen’s comments at Korea Blockchain Week 2026 are notable less for the prediction itself than for what sits behind it: two active SEC filings, fresh amendments from both issuers, and a product landscape that now includes staking exposure rather than simple spot tracking. The 21Shares and Canary applications, if approved, would give INJ something it has never had in the US market, namely fully regulated, brokerage-accessible exposure. The staked variant would go further, testing the boundaries of what yield-bearing crypto structures regulators will permit inside an ETF.
Injective’s parallel moves, SEC-registered transfer agent status and a MiCA white paper filing in Europe, suggest the project is building for regulated finance as a core strategy rather than a side effort. If the ETF timeline holds to Chen’s expectation, INJ would join the still-short list of Layer 1 tokens with US-listed fund exposure, a milestone that would carry implications well beyond Injective itself. The filings are active. The issuers are engaged. The chief executive expects movement before 2027. The market will now be watching the SEC docket for the next amendment, because in this process, paperwork is the signal.
